Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Longitudinal changes in patient characteristics as drivers of clinical outcomes in the Early Undifferentiated
Nathalie Carrier1, Javier Marrugo1,2, Misti L Paudel3
1Division of Rheumatology, Centre intégré universitaire de santé et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sherbrooke, QC, Canada.
Objective:
We investigated whether gradual clinical changes in RA patients diagnosed over two decades contributed to their improving outcomes during follow-up.
Methods:
A total of 840 consecutive early RA patients were recruited in the Early Undifferentiated PolyArthritis (EUPA) cohort and assessed up to 5 years. Recruitment was categorized into three periods: (1) preBIO (1998-2004), (2) INNOV (2005-2010) and (3) T2Tp (2011-2022). Inverse probability of treatment weighting (IPTW) was used to account for baseline variations over time periods. Multivariate generalized estimating equations (GEEs) with repeated measures identified predictors of outcomes.
Results:
The recruitment periods comprised 245, 266 and 329 recruited patients, respectively. After IPTW, baseline characteristics became largely similar across periods. Use of high-dose MTX and biologics markedly increased after 2005, remaining similar (MTX) or increasing slightly (biologics) in T2Tp relative to INNOV periods. Corticosteroid tapering accelerated and became more complete in the T2Tp period. In multivariable analyses, after balancing baseline characteristics and accounting for changes in diagnostic and therapeutic strategies over time, recruitment after 2011 remained strongly associated with faster and more prevalent ACR/EULAR remission but not with erosive status over follow-up. Despite improved clinical outcomes, improvement curves over 5 years for functional status and other patient-reported outcomes (PROs) remained unchanged across the three periods.
Conclusions:
Compared with the INNOV period, patients recruited after 2011 presented with milder baseline characteristics and showed evidence for an amplified response to treatment during follow-up, contributing to higher remission rates. Nonetheless, improvements of function and other PROs remained similar across recruitment periods.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
Longitudinal Research
Longitudinal Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation